muyuan liu

Prof. muyuan liu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Annals of Medicine
Verified
Journal Article
Open access
YLYoumian Lan
Youmian Lan
DLDongchen Liu
Dongchen Liu
BLBin Liang
Bin Liang
XSXuhong Song
Xuhong Song
LXLingzhu Xie
Lingzhu Xie
MLmuyuan liu
muyuan liu
Studies have examined the role of integrin α3 (ITGA3) in papillary thyroid carcinoma (PTC). However, the functional and molecular mechanism by which ITGA3 is involved in the progression of PTC remains poorly understood. To investigate the role of ITGA3 in PTC, raw PTC transcriptome data underwent comprehensive bioinformatics analyses, including differential expression, co-expression network, and enrichment analyses. ITGA3 expression was validated via immunohistochemistry and western blotting in PTC tissues. Cell functional assays and xenograft models assessed PTC cell behaviour. The potential mechanisms of ITGA3 were elucidated using bioinformatics analyses, western blotting, co-immunoprecipitation, and immunofluorescence. Finally, integration of ITGA3 expression with clinical parameters enabled nomogram construction for precise prediction of cervical lymph node metastasis (CLNM) in PTC. ITGA3 was upregulated in PTC and associated strongly with CLNM (79.5% vs. 53.84%, p = 0.016). ITGA3 expression enhanced PTC proliferation and migration in vitro and in vivo via cooperating with the MET protein tyrosine kinase, followed by phosphorylation of MET at Tyr1234/1235, and activation of ERK and PI3K/AKT signaling pathways. Furthermore, upregulation ITGA3 reduced phosphorylation at FAK-Tyr397 and Src-Tyr416 in PTC cells. Finally, a nomogram combining ITGA3 expression and clinical parameters for predicting CLNM was constructed and validated, achieving a ROC curve AUC of 0.719, suggesting potential application for PTC diagnosis. ITGA3 promotes PTC cell proliferation and migration by cooperating with MET to activate MET-ERK and MET-PI3K-AKT signalling. ITGA3-MET cooperation may serve as a potential therapeutic target.

9 September 2022 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
MLmuyuan liu
muyuan liu
LTLitian Tong
Litian Tong
MXManbin Xu
Manbin Xu
XXXiang Xu
Xiang Xu
HGHaipeng Guo
Haipeng Guo
HPHanwei Peng
Hanwei Peng
Background: In our previous cadaveric study, we highlighted the posterior auricular artery (PAA) as a potential landmark for early identification of facial nerve (FN) when performing parotidectomy. However, further clinical study is critically needed before this landmark could be applied in clinical practice.Methods: For 31 patients enrolled, we tried to identify the FN by the guide of the PAA during parotidectomy. Additionally, the FN function was evaluated during follow‐up.Results: PAA could be exposed in 28 out of 31 (90.3%) patients during parotidectomy. Moreover, the FN trunk could be identified by the guide of the PAA in all these 28 patients with identifiable PAA. Furthermore, no iatrogenic FN damage happened in this study and the transient FN dysfunction rate was 5.7%.Conclusion: The PAA is an ideal landmark for early identification of the FN trunk when performing parotidectomy.

1 July 2024 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
ZWZhaoting Wu
Zhaoting Wu
LTLihua Tang
Lihua Tang
YLYaozhen Lai
Yaozhen Lai
MLmuyuan liu
muyuan liu
LZLi Zhou
Li Zhou
Purpose: Struma ovarii is a highly specialized teratoma consisting primarily of mature thyroid tissue. However, malignant struma ovarii coexisting with thyroid carcinoma, not to mention autoimmune disease, is uncommon. Malignant struma ovarii complicated with papillary thyroid carcinoma, Hashimoto’s thyroiditis and polycystic ovarian syndrome has never been reported in literature. Patients and Methods: A 32-year-old female was admitted to our hospital due to a history of abdominal distension and menolipsis over the past half a year. Physical examination touched a 6 × 6 cm mass with a clear boundary, normal movement, and no pressing pain in the right adnexal area, Imaging revealed a cystic solid mass of 6 × 7 cm in the right ovary and the level of tumor markers including CA125, CA199, CA153, CEA, AFP were normal, but with low TSH and increased TPOAb, TGAb, TRAb. Laparoscopic right ovary tumor resection was performed, followed by comprehensive staging surgery, as well as thyroidectomy after pathologic diagnosis. The patient was diagnosed with a combination of follicular thyroid cancer from struma ovarii, papillary thyroid carcinoma and Hashimoto’s thyroiditis, along with polycystic ovarian syndrome. Immunohistochemical staining showed positivity for Ag, CK-pan, CK7, PAX8 and TTF-1 in the right ovarian mass, and the left thyroid was positive for the BRAF V600E mutation. Results: The patient underwent thyroxine suppression therapy and radioactive iodine 131I therapy after operation. Serum thyroglobulin was undetectable, and no signs of recurrence or metastasis were detected in the imaging examination at the 2-year follow-up. Conclusion: Malignant struma ovarii coexisting with thyroid carcinoma is rare. No report has been identified in literature review on the rare malignant struma ovarii coexisting with thyroid carcinoma, Hashimoto’s thyroiditis and polycystic ovarian syndrome. Our case can offer experience of diagnosis and treatment to some extent for such rare case. Therefore, it is essential to consider the association between ovarian tumors and the endocrine system. This case is valuable in understanding the diagnosis and management of such an unusual complicated disease.

26 August 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SXShaowei Xu
Shaowei Xu
HZHongxin Zheng
Hongxin Zheng
XLXiaoqi Liao
Xiaoqi Liao
MJManyu Jiang
Manyu Jiang
HPHanwei Peng
Hanwei Peng
MLmuyuan liu
muyuan liu
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor. Traditional treatments have unstable efficacy, with risks of relapse, drug resistance and side effects. Immunotherapy has achieved good results in recurrent/metastatic advanced HNSCC, but relevant research on its neoadjuvant application is insufficient. This study retrospectively analyzes clinical data to evaluate the efficacy and safety of PD-1 inhibitors as neoadjuvant therapy for LA-HNSCC, providing a scientific basis for treatment strategies. This study conducted a retrospective analysis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated at Shantou University Cancer Hospital from November 2020 to March 2024. The experimental group was administered neoadjuvant PD-1 inhibitor combined with chemotherapy, while the control group received chemotherapy alone. Efficacy was evaluated in accordance with RECIST 1.1 criteria, and treatment-related adverse events were graded based on CTCAE 5.0. SPSS 27.0 software and Kaplan-Meier method were employed for statistical analysis, with p0.05), with no significant difference in RECIST-based efficacy outcomes (P>0.05). The study group exhibited a significantly higher pathological downgrading rate and pathological complete response (pCR) (P = 0.032), a favorable safety profile, and improved overall survival (OS) (P = 0.044). Neoadjuvant immunochemotherapy was associated with improved overall survival, and surgery was associated with a lower risk of death. These findings are exploratory and require confirmation in larger prospective studies. Neoadjuvant immunochemotherapy was associated with improved pathological response and OS in LA-HNSCC, with an acceptable safety profile. These exploratory findings warrant confirmation in larger prospective studies.a retrospective analysis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated at Shantou University Cancer Hospital from November 2020 to March 2024. The experimental group was administered neoadjuvant PD-1 inhibitor combined with chemotherapy, while the control group received chemotherapy alone. Efficacy was evaluated in accordance with RECIST 1.1 criteria, and treatment-related adverse events were graded based on CTCAE 5.0. SPSS 27.0 software and Kaplan-Meier method were employed for statistical analysis, with p0.05), with no significant difference in RECIST-based efficacy outcomes (P>0.05). The study group exhibited a significantly higher pathological downgrading rate and pathological complete response (pCR) (P = 0.032), a favorable safety profile, and improved overall survival (OS) (P = 0.044). Neoadjuvant treatment regimen and surgical intervention were identified as factors associated with improved OS. These should be interpreted as exploratory given the sample size and group imbalance. Neoadjuvant immunochemotherapy was associated with improved pathological response and OS in LA-HNSCC, with an acceptable safety profile. These exploratory findings warrant confirmation in larger prospective studies. A retrospective analysis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated at Shantou University Cancer Hospital from November 2020 to March 2024. The experimental group was administered neoadjuvant PD-1 inhibitor combined with chemotherapy, while the control group received chemotherapy alone. Efficacy was evaluated in accordance with RECIST 1.1 criteria, and treatment-related adverse events were graded based on CTCAE 5.0. SPSS 27.0 software and Kaplan-Meier method were employed for statistical analysis, with p0.05), with no significant difference in RECIST-based efficacy outcomes (P>0.05). The study group exhibited a significantly higher pathological downgrading rate and pathological complete response (pCR) (P = 0.032), a favorable safety profile, and improved overall survival (OS) (P = 0.044). Neoadjuvant treatment regimen and surgical intervention were identified as factors associated with improved OS. These should be interpreted as exploratory given the sample size and group imbalance. Neoadjuvant immunochemotherapy was associated with improved pathological response and OS in LA-HNSCC, with an acceptable safety profile. These exploratory findings warrant confirmation in larger prospective studies. A retrospective analysis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated at Shantou University Cancer Hospital from November 2020 to March 2024. The experimental group was administered neoadjuvant PD-1 inhibitor combined with chemotherapy, while the control group received chemotherapy alone. Efficacy was evaluated in accordance with RECIST 1.1 criteria, and treatment-related adverse events were graded based on CTCAE 5.0. SPSS 27.0 software and Kaplan-Meier method were employed for statistical analysis, with p0.05), with no significant difference in RECIST-based efficacy outcomes (P>0.05). The study group exhibited a significantly higher pathological downgrading rate and pathological complete response (pCR) (P = 0.032), a favorable safety profile, and improved overall survival (OS) (P = 0.044). Neoadjuvant immunochemotherapy was associated with improved overall survival, and surgery was associated with a lower risk of death. These findings are exploratory and require confirmation in larger prospective studies. Neoadjuvant immunochemotherapy was associated with improved pathological response and OS in LA-HNSCC, with an acceptable safety profile. These exploratory findings warrant confirmation in larger prospective studies.